Travoprost intracameral implant, when combined with cataract surgery, significantly reduces intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, according to a study.
The 12-month, single-arm trial enrolled patients with age-related cataracts and an unmedicated mean diurnal IOP of 24 mmHg or higher. Participants underwent uncomplicated phacoemulsification and received a travoprost intracameral implant during the procedure. Follow-ups occurred at day 2 or 3, week 2, week 6, and month 3.
At 3 months, there was a mean IOP reduction of 10.6 mmHg, with 97% of eyes achieving a ≥20% reduction and 91% reaching an IOP of ≤18 mmHg. The treatment was well-tolerated, with no serious adverse events and minimal side effects, the most common being dry eye (6.7%).
Reference
Singh IP, Voskanyan LA, Barber KM, et al. Safety and efficacy of travoprost intracameral implant administered in combination with cataract surgery. Ther Adv Ophthalmol. 2025;17:25158414241310275. doi: 10.1177/25158414241310275. PMID: 39959854; PMCID: PMC11829291.
Related Content
